We serve Chemical Name:Ethyl 6-chloro-1H-indole-2-carboxylate CAS:27034-51-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Ethyl 6-chloro-1H-indole-2-carboxylate
CAS.NO:27034-51-1
Synonyms:1H-Indole-2-carboxylic acid, 6-chloro-, ethyl ester;Ethyl 6-chloroindole-2-carboxylate;6-chloro-1H-indole-2-carboxylic acid ethyl ester;6-chloroindole-2-carboxylic acid Ethyl ester;6-Chloro-2-Indolecarboxylic methyl ester;Ethyl 6-chloro-1H-indole-2-carboxylate;6-Chlor-indol-2-carbonsaeure-aethylester;MFCD03084731;1H-Indole-2-carboxylic acid,6-chloro-,ethyl ester;6-chlorindole-2-carboxylic acid ethyl ester
Molecular Formula:C11H10ClNO2
Molecular Weight:223.656
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:375.0±22.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.630
PSA:42.09000
Exact Mass:223.040009
LogP:3.70
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:III
Contact us for information like 1H-Indole-2-carboxylic acid, 6-chloro-, ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-chlorindole-2-carboxylic acid ethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-chloroindole-2-carboxylic acid Ethyl ester Use and application,6-Chlor-indol-2-carbonsaeure-aethylester technical grade,usp/ep/jp grade.
Related News: In the trial, 362 eligible patients were randomised (1:1) and received a fixed-dose intravenous infusion of 300mg anifrolumab or placebo every four weeks. Boc-Val-Pro-Arg-AMC hydrochloride salt manufacturers Recipharm joined the COVID-19 fight in December, signing on to produce the Moderna vaccine at its plant in Monts, France. The company hasn’t revealed if the new facilities will be engaged in COVID-19 vaccine production, though the plant in Morocco will “mirror” a new fill-finish line it added in France. disodium,4-[2,9-dimethyl-7-(4-sulfonatophenyl)-1,10-phenanthrolin-4-yl]benzenesulfonate suppliers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 1-Bromo-2-(bromomethyl)-4-nitrobenzene vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 1-Bromo-2-(bromomethyl)-4-nitrobenzene vendor & factory.
